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Abstract
Background: Acinetobacter baumannii has been associated with high morbidity and mortality rates, even in
pediatric patients. Therapeutic options are limited, especially when the strain is multidrug resistant.
Methods: Clinical and microbiological analyses of 4 cases of systemic infections caused by multi drug resistant
A. baumannii treated with colistin/vancomycin combination at a Pediatric Intensive Care Unit were performed in
order to explore the potential synergistic activity of colistin plus vancomycin. All the patients were treated with
colistin, meropenem and vancomycin.
Results: Four severe infections due to MDR A. baumannii were observed. All patients treated with colistin/
vancomycin combination had a positive outcome with no infection relapses. Most importantly, no significant
adverse events related to the simultaneous administration of COL plus VAN were observed. In our in-vitro
experiments, the synergistic effect of the combination COL plus VAN showed an early bactericidal activity even at
VAN concentration of 16 mg/L, which reflects the serum trough concentrations obtained in patients.
Discussion: An antimicrobial strategy based on the activity of colistin plus vancomycin was in-vitro and in-vivo
effective in life-threatening infections caused by multidrug-resistant A. baumannii in a Pediatric Intensive Care
Unit, in the absence of adverse effects. Colistin plus vancomycin were highly synergic and bactericidal against
carbapenem-resistant, colistin sensitive A. baumannii whereas the addition of meropenem did not enhance the
in-vitro activity of colistin plus vancomycin.
Conclusions: Our results confirm existing data on the potential synergistic activity of a therapeutic strategy
including colistin plus vancomycin and provide important new clinical information for its potential use as a
therapeutic option against MDR A. baumannii infections, especially in the pediatric population.
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Background
Acinetobacter baumannii has been recognized as a lead-
ing nosocomial pathogen associated with significant
increase of length of hospitalization and mortality rates,
even in the pediatric critical care units (PICUs) [1–5].
Moreover, therapeutic options are severely limited by
the emergence of strains resistant to most antibiotics
including carbapenems [6].
A few epidemic lineages of A. baumannii have been
considered to be responsible for the majority of the hos-
pital outbreaks worldwide, primarily the three inter-
national clonal lineages (ICLs) designated as ICL-I, ICL-II
and ICL-III [7]. Resistance to several antibiotics, in par-
ticular carbapenems, is the hallmark of the most success-
ful epidemic lineages [8]. Of note, an increasing incidence
of carbapenem resistance has recently been reported
among multi-drug resistant (MDR) ICL-II A. baumannii
from central Italy, with the emergence in 2009 of a major
clone carrying the blaOXA-23-like determinant [9].
Nowadays, the treatment of MDR A. baumannii infec-
tions represents a real challenge. Colistin (COL)-based
combinations, with or without the addition of high dose
of carbapenems, have been considered the milestone of
the treatment; however, in consideration of the growing
rate of resistance to several antimicrobial classes, innova-
tive approaches against this microorganism have been
investigated. Among these un-orthodox combinations,
COL plus glycopeptides resulted to be effective both in-
vitro and in animal models [10–13], with the potential
additional advantage of preventing the development of
COL resistance in COL sensitive strains [14, 15].
However, in the literature there are limited and anec-
dotal data regarding the use of this regimen in the clin-
ical practice, especially in the pediatric patients. In fact,
previous evidences were collected only throughout
retrospective analyses.
Based on the potential synergistic activity of COL plus
VAN, we report the in-vitro and in-vivo effectiveness of
an antimicrobial strategy consisting of COL plus VAN
plus meropenem (MEM) in four cases of systemic infec-
tions caused by MDR A. baumannii in a PICU.
Methods
Over a 2-months period, four cases of systemic infections
due to MDR A. baumannii treated with the combination
colistin plus vancomycin in patients hospitalized at PICU
of “Sapienza” University of Rome were observed. For each
patient, clinical and microbiological data were recorded.
Written informed consent for the inclusion in this work
was obtained from the patients or their legal guardians;
according to local regulations, no Ethical Committee
authorization is required in these cases [16, 17].
Isolates from clinical samples including blood, tra-
cheal aspirate and broncoalveolar lavage underwent
identification and antimicrobial susceptibility testing using
the VITEK-2 (Bio-Merieux, Marcy l’Etoile, France) auto-
mated system.
Molecular analyses were performed in two strains
whereas all the microbiological analyses were performed
only on the case index strain.
To define the A. baumannii sequence group (SG), two
multiplex PCRs designed to selectively amplify group 1
or group 2 alleles of the ompA, csuE and blaOXA-51-
like genes were performed, and allelic profiles were
interpreted according to Turton et al. [18]. The presence
of four groups of OXA-carbapenemase genes (namely
blaOXA-23-like, blaOXA-24-like, blaOXA-51-like and
blaOXA-58-like) was detected by PCR using a multiplex
assay as previously described [19, 20].
Minimal inhibitory concentrations (MICs) and loga-
rithmic minimal bactericidal concentrations (MBClog)
of MEM, COL, VAN and rifampin (RIF) were deter-
mined by broth macrodilution method (BMD) in cation-
adjusted Mueller Hinton broth (CAMHB) according to
the Clinical Laboratory Standards Institute (CLSI) guide-
lines [21]. For all COL testing, a polysorbate-80 (Sigma-
Aldrich) final concentration of 0.002 % was used [22].
The MIC was defined as the lowest concentration of anti-
biotic that completely inhibited visible growth whereas the
MBClog was defined as the lowest antimicrobial concen-
tration which killed ≥99.9 % of the initial bacterial count
(i.e., ≥3 log10 CFU/ml) at 24 h.
Synergy tests were performed throughout the checker-
board method at different concentrations of the follow-
ing antibiotic combinations: COL +MEM, COL + RIF,
COL + VAN, MEM+VAN.
Complete synergism was defined as FIC-index (FICI)
≤0.5, partial synergism as FICI >0.5 < 1, additivity as
FICI ≥1 < 2, antagonism as FICI ≥2. A final inoculum
of ~5 × 105 CFU/ml was used for all in-vitro experi-
ments. In addition, the Susceptible Breakpoint Indices
(SBPI) of the tested combinations was calculated [10].
To determine VAN and RIF susceptibility, the authors
used breakpoints consistent with those set for Gram-
positive organisms by the CLSI and EUCAST [10].
Furthermore, the activity of COL, VAN and MEM,
alone and in combination, was investigated by time-kill
studies using an initial inoculum of ~5 × 105 CFU/
mL. As stated before, the time kill studies were con-
ducted only on case index strain. At 2, 4, 6, 8 and
24 h time points, the number of CFU was counted.
The following concentrations were used for killing tests:
1 ×MIC COL, 1 ×MIC VAN, 1 ×MIC MEM, 0.5 ×MIC
COL + 0.25 ×MIC VAN, 0.5 ×MIC COL + 0.125 ×MIC
VAN, 0.5 ×MIC COL + 0.5 ×MIC MEM, 0.5 ×MIC COL
+ 0.25 ×MIC MEM, 0.5 ×MIC COL + 0.25 ×MIC VAN+
0.5 ×MIC MEM and 0.5 ×MIC COL + 0.125 ×MIC VAN
+ 0.5 ×MIC MEM.
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Bactericidal activity was defined as a ≥3-log10 CFU/mL
reduction of the initial bacterial count at each time point.
Synergy was defined as a ≥2-log10 decrease in CFU/mL
between the combinations and its most active constituent
after 24 h. The detection limit was 10 CFU/mL.
Results
Case series
Four severe infections [2 bloodstream infections (BSIs),
1 ventilator associated pneumonia (VAP), 1 BSI plus
VAP] due to MDR A. baumannii were observed at the
PICU. Clinical and microbiological data of the index
case are reported in Table 1. The index case was a
newborn with a severe sepsis caused by MDR and COL
sensitive A. baumannii. The patient was initially treated
for 5 days with intravenous (i.v.) COL (6 mg/kg equiva-
lent to 75,000 IU/kg per day, in three divided doses
following a loading dose of 6 mg/kg) and RIF (10 mg/kg
per day). However, due to worsening of the clinical con-
ditions, VAN (40 mg/kg per day, in three divided doses)
and MEM (60 mg/kg per day, in three divided doses)
were added to COL, whereas RIF was stopped because
of hepatic toxicity. A prompt clinical response was
observed and the patient completed a 17 days treatment
course. Subsequently, the patient developed a late onset
uncomplicated urinary tract infection caused by the
same MDR A. baumannii (Fig. 1 and Table 1).
Based on the favourable outcome of the index case,
the 3 following cases were treated with the combination
COL plus VAN plus MEM. In particular, in case#2 this
strategy was started after an initial failure of the COL
plus RIF treatment whereas the remaining two cases
were both treated with the triple combination as initial
therapy. The patients had a positive outcome with no
infection relapses. Most importantly, no significant ad-
verse events related to the simultaneous administration
of COL plus VAN were observed.
Microbiological studies
Molecular analyses were performed on two clinical
strains (case index and case#2). Both isolates were PCR-
positive for the blaoxa-51-like gene, confirming their
identity as A. baumannii [23].
Multiplex PCRs for identification of the SG yielded the
111 allelic profiles (corresponding to SG 1 according to
Turton et al. [18]), indicating that both isolates belonged
to the ICL-II (Additional file 1: Figure S1).
Carbapenem resistance was associated with the pres-
ence of the blaOXA-23-like carbapenem hydrolyzing
oxacillinase gene (Additional file 2: Figure S2).
According to the VITEK-2 system, the strains of the four
patients were similar, and were resistant to gentamicin, cip-
rofloxacin, amoxicillin/clavulanate, cefotaxime, ertapenem,
impenem, meropenem, trimethoprim/sulfamethoxazole,
tigecycline and sensitive only to COL (MIC = 0.5 mg/L).
Additional microbiological assays to assess the poten-
tial synergism of COL plus VAN were conducted only
on the index strain.
Using the MBD method, MICs/MBCs were 1/1, 128/
256, 8/128 and 128/256 mg/L for COL, MEM, RIF and
VAN, respectively. A complete synergism (FIC index <0.5)
was observed for COL +VAN, COL +MEM and COL +
RIF whereas the combination MEM+VAN showed addi-
tivity. The SBPI values were 8.12, 16.06, 12 and 0.04 for
COL +VAN, COL +MEM, COL + RIF and MEM+VAN,
respectively.
In particular, the combination COL + VAN showed
an absence of growth at the following concentrations:
0.5 ×MIC COL (0.5 mg/L) + 0.25 ×MIC VAN (32 mg/L),
0.5 ×MIC COL (0.5 mg/L) + 0.125 ×MIC VAN (16 mg/
L), 0.25 ×MIC COL (0.25 mg/L) + 0.25 ×MIC VAN
(32 mg/L), 0.25 ×MICCOL (0.25 mg/L) + 0.125 ×MIC
VAN (16 mg/L).
The combination COL +MEM+VAN at the concentra-
tions of 0.5 ×MIC COL (0.5 mg/L) + 0.5 ×MIC MEM
(64 mg/L) + 0.25 ×MIC VAN (32 mg/L) and 0.5 ×MIC
COL (0.5 mg/L) + 0.5 ×MIC MEM (64 mg/L) + 0.125 ×
MIC VAN (16 mg/L) showed in-vitro activity. Given the
high bacteriostatic activity of the combinations COL +
VAN and COL+VAN+MEM, we decided to perform bac-
tericidal analyses by using different concentration of such
antimicrobials.
Table 1 Clinical characteristics and microbiological data of patients




Treatment (duration, days) Outcomed
Initial Definitive
Case#1 3 moa Pierre Robin Syndrome Septic shock
(A. baumannii BSI)
BSI RIF + COL (5) VAN + COL +MEM (12) Late relapse (UTI)
Cured
Case#2 21 ys Spastic tetraparesis;
dysphagia
Respiratory failureb VAP & BSI RIF + COL (5) VAN + COL +MEM (15) Cured
Case#3 25 ys Spastic tetraparesis Respiratory failureb BSI VAN + COL +MEM (16) VAN + COL +MEMc Cured
Case#4 6 mo None ARDS VAP VAN + COL +MEM (19) VAN + COL +MEMc Cured
COL colistin, VAN vancomycin, RIF rifampin, MEM meropenem, UTI urinary Tract Infection, BSI bloodstream infection, VAP Ventilator-Acquired Pneumonia,
ARDS Acute Respiratory Distress Syndrome
(a): Case-index; (b): caused by the underlying disease; (c): in cases #3-4 the initial therapy was the definitive one; (d): at least 3-months follow-up
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In the killing experiments, VAN, MEM and COL alone
showed only a slight decrease of CFU/mL at 2 h, 4 h,
and 6 h time points; however, a significant re-growth
was observed at 24 h for all antimicrobials (Fig. 2).
When the combination COL +VAN was tested, bacteri-
cidal activity was observed after 2 h at concentrations of
0.5 ×MIC COL (0.5 mg/L) + 0.25 ×MIC VAN (32 mg/L)
and 0.5 ×MIC COL (0.5 mg/L) + 0.125 ×MIC VAN
(16 mg/L), which was maintained until 24 h (Fig. 2a). In
addition, these combinations were synergic at 24 h. Of
note, the latter combination reflects the serum trough
concentrations of VAN which can be achieved during
therapy (16 mg/L).
The combinations 0.5 ×MIC COL (0.5 mg/L) + 0.5 ×
MIC MEM (64 mg/L) and 0.5 ×MIC COL (0.5 mg/L) +
0.25 ×MIC MEM (32 mg/L) showed a bactericidal activ-
ity at 6 h, which was observed until 24 h (Fig. 2b).
The triple combinations 0.5 ×MIC COL (0.5 mg/L)
COL + 0.5 ×MIC MEM (64 mg/L) + 0.25 ×MIC VAN
(32 mg/L) and 0.5 ×MIC COL (0.5 mg/L) COL + 0.5 ×
MIC MEM (64 mg/L) + 0.125 ×MIC VAN (16 mg/L)
were found to be bactericidal at 6 h, with absence of
growth at 24 h (Fig. 2c).
Discussion
In this report, we described the in-vitro and in-vivo
effectiveness of a combination containing COL, MEM
and VAN against MDR A. baumannii causing systemic
infections at a PICU.
Nowadays, the ability of A. baumannii to rapidly
acquire antibiotic resistance has been recognized as an
important therapeutic challenge. Therefore, the use of
COL has been recently reviewed and combinations of
COL plus RIF or tigecycline or ampicillin-sulbactam
have been used in critically ill adults and children.
However, tigecycline safety and efficacy have not been
established yet in pediatric patients, and its use in these
subjects is so far not recommended [24–29].
The usefulness of a combination therapy has been
highlighted by a recent clinical trial in patients with life-
threatening infections due to MDR A. baumannii [30].
Despite the 30-day mortality was not reduced by the
addition of RIF to COL (at a daily dosage of 6 MUI), an
increased rate of A. baumannii eradication was observed
relative to COL alone [30].
The in-vitro synergistic activity of COL-based regimens
in COL-susceptible and COL-resistant A. baumannii
strains is an area of active investigation [25–29]. Among
innovative approaches, the combination of COL plus
other antimicrobials usually used against Gram-positive
bacteria has recently gained interest. Potent in-vitro syner-
gistic interactions between COL and daptomycin have
been described, although the beneficial effects of this
combination were limited only to COL susceptible isolates
[31]. A study on the activity of COL plus telavancin (a
novel lipoglycopeptide antibiotic with a narrow anti-
Gram-positive spectrum) reported a marked synergism
both in checkerboard and time–kill assays against COL-
susceptible MDR A. baumannii isolates [32].
However, COL + VAN is regarded to as the most
promising combination. A pioneer study by Gordon
et al. first described an unexpected potent synergism
and a sustained bactericidal activity of the VAN+COL
combination against MDR COL-sensitive A. baumannii
Fig. 1 Clinical and therapeutic features of case-index MDR A. baumannii bacteremia. Procalcitonin levels increased up to 7 mg/L under treatment
with COL + RIF, which was expression of treatment failure. Rather, it started to decrease under COL + VAN +MEM therapy and reached the normal
value after 15 days of such therapy. The decreasing levels of procalcitonin following therapy with COL + VAN +MEM was expression of treatment
success. COL: Colistin, VAN: Vancomycin, RIF: Rifampin, MEM: Meropenem
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[10], and similar effects were later reported for COL-
resistant strains [12]. Interestingly, the bactericidal activity
was only slightly delayed in COL-resistant compared to
the susceptible isolates, suggesting that the mechanisms
responsible for COL resistance in A. baumannii strains
do not significantly affect the synergism of the VAN +
COL combination. However, few anecdotal data on the
use of this regimen in pediatric patients are available,
and these were collected only through retrospective
analyses [33, 34].
The rationale of using COL plus VAN resides on the
hypothesis that COL increases the permeability of the
outer membrane, thereby enhancing the antibacterial
activity of large sized hydrophobic molecules, such as
VAN, which are normally excluded by the Gram-negative
outer membrane. Thus, the membrane-perturbing proper-
ties of COL could allow VAN to reach its periplasmic
target at inhibitory concentrations [10]. The importance
of the cell-permeabilizing properties of COL in determin-
ing synergisms with unconventional antimicrobials is
consistent with the absence of in-vitro synergism observed
in our study for the MEM+VAN combination.
Notably, we observed a clear clinical and microbio-
logical response in all the patients treated with the new
therapeutic approach consisting of COL plus VAN plus
MEM, in the absence of adverse events. Our decision to
combine VAN with COL and MEM was motivated by the
lack of response to the COL plus RIF combination in the
index case. This led us to suppose that a new infection
was simultaneously present, and pending microbiological
Fig. 2 Time–kill studies for colistin (COL), meropenem (MEM) and vancomycin (VAN), alone and in combination, against MDR A. baumannii. a The
bactericidal activity of COL + VAN is represented. Values in bracket represent the actual concentration (mg/L). b The bactericidal activity of COL +
MEM is represented. Values in bracket represent the actual concentration (mg/L). c The bactericidal activity of COL +MEM + VAN is represented.
The actual concentrations of the triple combinations are: 0.5 × MIC COL (0.5 mg/L) COL + 0.25 × MIC VAN (32 mg/L) + 0.5 × MIC MEM (64 mg/L)
and 0.5 × MIC COL (0.5 mg/L) COL + 0.125 × MIC VAN (16 mg/L) + 0.5 × MIC MEM (64 mg/L). The dashed horizontal line represents a reduction of
3 log10 cfu/mL compared with the initial bacterial count. GC, growth control
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data, broad spectrum empiric therapy was started. Consid-
ering that no microorganisms other than MDR A. bau-
mannii were documented, we were impressed by the
quick clinical response of A. baumannii BSI to COL +
VAN+MEM, and we wondered which role the glycopep-
tide and carbapenem could have had in this combination.
Clinical results were supported by in-vitro studies,
showing not only a bacteriostatic synergistic activity of
COL plus VAN, but also a potent bactericidal activity.
These findings corroborate existing data on the synergis-
tic activity of COL plus VAN [33, 34], thus providing
novel clinical information for its potential use as a viable
therapeutic option against MDR A. baumannii infec-
tions in the pediatric population.
Nevertheless, it should be pointed out that all the
patients had also received MEM together with COL and
VAN. Thus, the contribution of MEM to the clinical
resolution of the infections should be taken into
account. Time-kill results showed that the addition of
MEM to COL + VAN did not enhance the bactericidal
activity of the combination COL + VAN.
Interestingly, the combination of COL + VAN resulted
to be more rapidly bactericidal than both COL +MEM
and COL + VAN +MEM combinations. However, the
combination COL +MEM showed an absence of growth
at 6 h, whereas COL + VAN, although quickly bacteri-
cidal (i.e., at 2 h), still showed some bacterial growth at
6 h and 8 h. The meaning of these slight differences be-
tween COL + VAN and COL +MEM observed in vitro,
and their possible clinical implications, deserve further
investigations.
In our in-vitro experiments, the synergistic effect of
the combination COL plus VAN was impressive, with an
early bactericidal activity even at VAN concentration of
16 mg/L, which reflects the serum trough concentra-
tions obtained in patients [35]. Moreover, the addition of
high concentrations of MEM, which are not easily
achieved in patient’s serum despite prolonged infusion,
did not enhance the in-vitro synergistic activity of COL
+ VAN. These results might be of crucial importance in
the clinical practice, considering the deleterious effects
that extensive use carbapenems has in the critical care
setting, such as the selection of carbapenemase produ-
cing K. pneumoniae, carbapenem-resistant Pseudomonas
aeruginosa and Stenotrophomonas maltophilia. In our
opinion, the implementation of a therapeutic strategy
aimed at treating infections caused by MDR A. bauman-
nii based on the combination COL + VAN, without the
addition of MEM, should be investigated in larger stud-
ies, in order to confirm these intriguing results in terms
of clinical and microbiological effectiveness.
Although molecular analyses were performed only on
two isolates, the temporal and spatial spread of infec-
tions into the PICU is suggestive of an outbreak caused
by a single clone of MDR A. baumannii. In fact, both
isolates belonged to the ICL-II, carried the blaOXA-23-
likecarbapenemase gene and showed the MDR pheno-
type. Moreover, they shared the typical features of the
main epidemic ICL-II clone widespread in central Italy
[9, 36]. It is therefore tempting to speculate that the
therapeutic protocol reported in this study would prove
to be successful for the treatment of other infections
caused by this worrisome A. baumannii clone, not only
in the PICU setting.
Whether the COL + VAN combination could be asso-
ciated with an increased risk of renal toxicity is still
matter of discussion. In fact, one study reported that the
rate of acute kidney injury is significantly higher in the
group treated with COL plus VAN than in those
receiving only COL alone [33], whereas another study
reported similar nephrotoxicity in patients treated with
and without a COL-glycopeptide combination [34]. In
the literature, there are limited data regarding the po-
tential nephrotoxicity of COL-based combinations in
pediatric patients. However, it has been shown that only
a minority of critically ill children receiving intravenous
COL for MDR Gram negative infections developed
renal toxicity, even when COL was co-administered
with VAN [37].
Conclusion
Our study provides additional evidence that the innova-
tive combination of COL plus VAN, together with the
possible association of MEM, could represent a life-
saving therapy in selected cases of severe infections
caused by MDR A. baumannii. Although our data refer
to only four cases of life-threatening infections likely due
to a single clone of MDR A. baumannii, it is plausible
that this strategy will serve as an effective and safe thera-
peutic option in severe infections caused by MDR A.
baumannii.
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